Clinical Momentum HiberCell is a clinical stage oncology company advancing first-in-class agents that modulate stress pathways and anti-tumor immunity, with multiple assets in Phase 1 and Phase 2 trials. Targeting metastasis, resistance, and relapse, this signals ongoing need for collaboration across translational and clinical development partners.
PLATFORM CAPABILITIES The QuAD[3] platform for AI-driven drug discovery and development positions HiberCell to accelerate identification and optimization of candidates, presenting a cross-sell opportunity for technology licensing, data services, and collaboration on AI-enabled research programs.
Key PROGRAMS Lead candidates HC-5404 (PERK) and HC-7366 (GCN2) in early clinical stages, plus odetiglucan (innate immune modulation) in Phase 2, creating multiple entry points for CROs, contract manufacturing, and regulatory consulting as they advance.
Strategic PARTNERSHIPS Recent AACR activities and preclinical data presentations indicate active engagement with academic and industry ecosystems, suggesting opportunities for co-development deals, data-sharing arrangements, and co-sponsored trials with oncology-focused biotechs and pharma.
Financial READINESS With substantial funding to date and revenue in the tens of millions, HiberCell likely has readiness for partnered research programs, licensing discussions, and expanded clinical trial collaborations to accelerate development while managing capital needs.